Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
NCT06593977

Evaluation of Dynavisc in Pain Reduction Following Revision Surgery for Persistent or Recurrent Carpal Tunnel Syndrome

Led by FzioMed · Updated on 2026-04-06

50

Participants Needed

4

Research Sites

79 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The trial will evaluate the efficacy of DYNAVISC in subjects with a diagnosis of persistent or recurrent carpal tunnel syndrome. This is a prospective, multicenter, randomized, evaluator-blinded clinical trial. Results will be stratified based on the method used for median nerve coverage: Group 1 (standard of care surgery followed by DYNAVISC surrounding the median nerve, n=25 participants), Group 2 (standard of care surgery followed by coverage of the median nerve with a hypothenar fat pad flap, n=25

CONDITIONS

Official Title

Evaluation of Dynavisc in Pain Reduction Following Revision Surgery for Persistent or Recurrent Carpal Tunnel Syndrome

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed and dated informed consent form
  • Willingness to follow all study procedures and be available for the study duration
  • Aged 18 to 65 years
  • In good general health
  • Experiencing recurrence or persistence of hand pain after prior carpal tunnel release surgery
  • At least one positive physical exam test: Phalen, Tinel's, or monofilament test
  • ENMG shows median nerve velocity and abnormalities consistent with carpal tunnel syndrome
Not Eligible

You will not qualify if you...

  • Unable to understand the trial or sign informed consent
  • Unable or unwilling to attend all study visits and complete data forms
  • Active infection needing medication
  • Diabetes requiring medication
  • Collagen disorders
  • Hypothyroidism requiring medication
  • Rheumatoid arthritis requiring medication
  • Autoimmune disease requiring medication
  • Cervical nerve compression
  • Blood disorders
  • Lacertus fibrosis
  • Psychiatric disorder requiring treatment
  • Subject of workers compensation claim
  • History of cancer except basal or squamous cell skin cancer
  • Known allergy to DYNAVISC components
  • Currently participating in another clinical trial

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

UZ Leuven

Leuven, Belgium, Belgium, 3000

Actively Recruiting

2

AZ Delta

Roeselare, Belgium, Belgium, 8800

Actively Recruiting

3

Hospital Angelina Caron

Araçatuba, Brazil, Brazil, 83430-973

Actively Recruiting

4

Azienda Ospedale Universita Padova

Padova, Italy, Italy, 35128

Actively Recruiting

Loading map...

Research Team

G

Gere diZerega, MD

CONTACT

S

Stephanie Cortese, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here